Comparison of CT Volumetry and RECIST to Predict the Treatment Response and Overall Survival in Gastric Cancer Liver Metastases

다국어 초록 (Multilingual Abstract)

Purpose The aim of this study was to compare the diameter and volume of liver metastases on CT images in relation to overall survival and tumor response in patients with gastric cancer liver metastases (GCLM) treated with chemotherapy.
Materials and Methods We recruited 43 patients with GCLM who underwent chemotherapy as a first-line treatment. We performed a three-dimensional quantification of the metastases for each patient. An independent survival analysis using the Response Evaluation Criteria in Solid Tumors (RECIST) was performed and compared to volumetric measurements. Overall survival was evaluated using Kaplan-Meier analysis and compared using Cox proportional hazard ratios following univariate analyses.
Results When patients were classified as responders or non-responders based on volumetric criteria, the median overall survival was 23.6 months [95% confidence interval (CI), 8.63–38.57] and 7.6 months (95% CI, 3.78–11.42), respectively (p = 0.039). The volumetric analysis and RECIST of the non-progressing and progressing groups showed similar results based on the Kaplan- Meier method (p = 0.006) and the Cox proportional hazard model (p = 0.008).
Conclusion Volumetric assessment of liver metastases could be an alternative predictor of overall survival for patients with GCLM treated with chemotherapy.

참고문헌 (Reference)

1 Seymour L, "iRECIST : guidelines for response criteria for use in trials testing immunotherapeutics" 18 : e143-, 2017

2 Gehan EA, "Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?" 92 : 179-181, 2000

3 Lee SM, "Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer" 34 : 430-440, 2009

4 Kikuchi S, "Tumor volume : a novel prognostic factor in patients who undergo curative resection for gastric cancer" 385 : 225-228, 2000

5 Escudier B, "Sorafenib in advanced clear-cell renal-cell carcinoma" 356 : 125-134, 2007

6 Grothey A, "Response-independent survival benefit in metastatic colorectal cancer : a comparative analysis of N9741 and AVF2107" 26 : 183-189, 2008

7 Tirkes T, "Response criteria in oncologic imaging : review of traditional and new criteria" 33 : 1323-1341, 2013

8 Reiner CS, "Preoperative liver volumetry: how does the slice thickness influence the multidetector computed tomography- and magnetic resonance-liver volume measurements?" 33 : 390-397, 2009

9 Motzer RJ, "Pazopanib versus sunitinib in metastatic renal-cell carcinoma" 369 : 722-731, 2013

10 Adam R, "Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?" 27 : 1829-1835, 2009

11 Alberts SR, "Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer : a North Central Cancer Treatment Group phase II study" 23 : 9243-9249, 2005

12 Ryu T, "Oncological outcomes after hepatic resection and/or surgical microwave ablation for liver metastasis from gastric cancer" 42 : 100-105, 2019

13 Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)" 45 : 228-247, 2009

14 National Comprehensive Cancer Network, "NCCN clinical practice guidelines in oncology (NCCN guidelines). Gastric cancer, version 2. 2018"

15 Katherine M. Krajewski, "Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities" 대한영상의학회 18 (18): 28-41, 2017

16 Jaffe CC, "Measures of response : RECIST, WHO, and new alternatives" 24 : 3245-3251, 2006

17 Shinagare AB, "Liver metastases in the era of molecular targeted therapy : new faces of treatment response" 201 : W15-28, 2013

18 Guideline Committee of the Korean Gastric Cancer Association, "Korean Practice Guideline for Gastric Cancer 2018; Evidence-based, Multi-disciplinary Approach" 대한위암학회 19 (19): 1-48, 2019

19 Shirabe K, "Hepatic resection for the treatment of liver metastases in gastric carcinoma: review of the literature" 8 : 89-92, 2006

20 Ajani JA, "Gastric cancer, version 3. 2016, NCCN clinical practice guidelines in oncology" 14 : 1286-1312, 2016

21 Ito H, "Gastric cancer liver metastasis : optimal management for oligo-metastatic disease" 37 : 136-136, 2019

22 Aesun Shin, "Gastric Cancer Epidemiology in Korea" 대한위암학회 11 (11): 135-140, 2011

23 Schlansky B, "Epidemiology of noncardia gastric adenocarcinoma in the United States" 106 : 1978-1985, 2011

24 이인선, "Comparison of the Response Evaluation Criteria in Solid Tumors with Volumetric Measurement for Evaluation of Response and Overall Survival with Liver Metastases from Colorectal Cancer" 대한영상의학회 80 (80): 906-918, 2019

25 Hwang JE, "Combination of percutaneous radiofrequency ablation and systemic chemotherapy are effective treatment modalities for metachronous liver metastases from gastric cancer" 31 : 25-32, 2014

26 Wagner AD, "Chemotherapy in advanced gastric cancer : a systematic review and meta-analysis based on aggregate data" 24 : 2903-2909, 2006

27 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015" 대한암학회 50 (50): 303-316, 2018

28 Renzulli M, "Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma?" 279 : 432-442, 2016

29 Hallinan JT, "CT volumetry for gastric carcinoma : association with TNM stage" 24 : 3105-3114, 2014

30 Prasad SR, "CT tumor measurement for therapeutic response assessment : comparison of unidimensional, bidimensional, and volumetric techniques initial observations" 225 : 416-419, 2002

31 Sohaib SA, "CT assessment of tumour response to treatment : comparison of linear, cross-sectional and volumetric measures of tumour size" 73 : 1178-1184, 2000

32 Desar IM, "Beyond RECIST : molecular and functional imaging techniques for evaluation of response to targeted therapy" 35 : 309-321, 2009

33 Chun YS, "Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases" 302 : 2338-2344, 2009

34 Trillet-Lenoir V, "Assessment of tumour response to chemotherapy for metastatic colorectal cancer : accuracy of the RECIST criteria" 75 : 903-908, 2002

35 Egger ME, "Assessment of chemotherapy response in colorectal liver metastases in patients undergoing hepatic resection and the correlation to pathologic residual viable tumor" 216 : 845-856, 2013

36 Yang JC, "A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer" 349 : 427-434, 2003

37 Kikuchi S, "A new staging system based on tumor volume in gastric cancer" 21 : 2933-2936, 2001

38 Banerjee S, "A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma" 62 : 792-800, 2015